News

Add-on treatment with sotatercept, an investigational therapy for pulmonary arterial hypertension (PAH) now under regulatory review in the U.S., was predicted to prolong survival by about threefold relative to standard of care therapy alone in a recent analysis. The prediction model was built using short-term data from the…

A professor of pediatric cardiology at Stanford University School of Medicine will receive the American Heart Association 2023 Research Achievement Award, in recognition of her work in pulmonary arterial hypertension (PAH). Marlene Rabinovitch, MD, will receive the award Nov. 12 during the Presidential Session of the Association’s Scientific…

The ARRDC3 gene — implicated in inflammation and cell growth — may be a ferroptosis-related biomarker and treatment target in chronic thromboembolic pulmonary hypertension (CTEPH), according to a new study. Ferroptosis is an iron-dependent type of cell death involved in the damage of lung blood vessels and in lung…

The pulmonary hypertension (PH) community will be busy raising awareness and funds for research this November as they recognize Pulmonary Hypertension Awareness Month.   Leading these efforts is the Pulmonary Hypertension Association (PHA), the country’s oldest and largest nonprofit dedicated to the PH community. The…

Higher pressure in the heart’s top left chamber — a parameter called pulmonary arterial wedge pressure (PAWP) — is a likely predictor of poorer outcomes in people with pulmonary hypertension (PH) due to left heart disease, a study reports. PAWP was measured using the inhaled nitric oxide (iNO) vasoreactivity…

Immune-related genes that could serve as potential therapeutic targets for pulmonary arterial hypertension (PAH) were identified in a recent study. Among them was ROCK2, which was found to have increased gene activity in PAH patients’ lung tissue and animal models. Therapeutic molecules to inhibit the ROCK2 protein are already being…

Triple combination therapy — used to target multiple pathways — improves lung and heart function in pulmonary arterial hypertension (PAH) patients, according to real-world data from a racially diverse group. The combo therapy resulted in a significant easing of disease severity, with no patient classified as high risk. Being…

A heart transplant may resolve the pulmonary hypertension (PH) often found in children with heart failure — the organ’s inability to pump enough blood to meet the body’s needs, a small study found. After the transplant, however, it took longer for blood pressure to normalize in children with congenital…

Four proteins related to a pro-inflammatory signaling molecule called TNF-alpha may serve as biomarkers to predict mortality in adults with pulmonary hypertension (PH) caused by left heart failure, a new study shows. Elevated blood levels of two such proteins, both belonging to the TRAIL family, correlated with most standard…

Beyond Air has been given an innovative technology contract from Vizient for its LungFit PH system, which was approved in the U.S. last year to administer nitric oxide to treat persistent pulmonary hypertension of the newborn (PPHN). “We’re very happy and honored…

Most adults with pulmonary arterial hypertension (PAH) experience no worsening and may even see a reduction in the severity of their symptoms after being on treatment with Uptravi (selexipag) for up to about 1.5 years. That’s according to a new analysis of data from all patients who took…

Researchers have identified three proteins — NID1, C1QTNF1, and CRTAC1 — in the bloodstream of people with pulmonary hypertension (PH) whose presence accurately predicted the failure of the heart’s right ventricle (RV) and related outcomes, a study reports. The proteins may serve as biomarkers to assess disease progression and…